Spero Therapeutics (SPRO) Stock Forecast, Price & News

Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

Is Spero Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Spero Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRO, but not buy additional shares or sell existing shares.
View analyst ratings for Spero Therapeutics or view top-rated stocks.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 1,650,000 shares, a decline of 55.3% from the April 30th total of 3,690,000 shares. Based on an average daily trading volume, of 634,900 shares, the days-to-cover ratio is currently 2.6 days. Approximately 6.8% of the company's shares are sold short.
View Spero Therapeutics' Short Interest.

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Spero Therapeutics.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) released its earnings results on Monday, May, 16th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.87) by $0.14. Spero Therapeutics had a negative trailing twelve-month return on equity of 116.93% and a negative net margin of 792.03%. During the same period last year, the company posted ($0.66) EPS.
View Spero Therapeutics' earnings history.

What price target have analysts set for SPRO?

5 Wall Street analysts have issued 1-year price objectives for Spero Therapeutics' shares. Their forecasts range from $5.00 to $70.00. On average, they anticipate Spero Therapeutics' share price to reach $28.33 in the next twelve months. This suggests a possible upside of 2,184.9% from the stock's current price.
View analysts' price targets for Spero Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the following people:

• Dr. Ankit Mahadevia M.D., MBA, Co-Founder, Pres, CEO & Director (Age 41, Pay $924.28k) (LinkedIn Profile)
• Mr. Satyavrat Shukla C.F.A., CFO & Treasurer (Age 50, Pay $788.84k)
• Ms. Cristina Larkin, Chief Operating Officer (Age 52, Pay $654.95k)
• Dr. Thomas R. Parr Jr., Ph.D., Chief Scientific Officer (Age 68)
• Ted Jenkins, VP & Head of Investor Relations
• Ms. Tamara Lynn Joseph L.L.M., Chief Legal Officer (Age 59)
• Mr. David Musselman, Sr. VP of Sales & Market Access
• Mr. James P. Brady, Chief Human Resource Officer
• Mr. Timothy Keutzer, Chief Devel. Officer (Age 54)
• Dr. David A. Melnick M.D., Chief Medical Officer (Age 70)

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics CEO Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among Spero Therapeutics' employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Spero Therapeutics' key competitors?

Some companies that are related to Spero Therapeutics include Matinas BioPharma (MTNB), KemPharm (KMPH), Impel Pharmaceuticals (IMPL), Vaccitech (VACC), Inozyme Pharma (INZY), TFF Pharmaceuticals (TFFP), Allakos (ALLK), PDS Biotechnology (PDSB), Savara (SVRA), Xeris Biopharma (XERS), Avadel Pharmaceuticals (AVDL), AVEO Pharmaceuticals (AVEO), Clene (CLNN), ContraFect (CFRX) and Assertio (ASRT).
View all of SPRO's competitors.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.19%), Rock Springs Capital Management LP (3.02%), State Street Corp (1.52%), Dimensional Fund Advisors LP (1.24%), Northern Trust Corp (0.73%) and Royal Bank of Canada (0.60%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends for Spero Therapeutics.

Which major investors are selling Spero Therapeutics stock?

SPRO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Granahan Investment Management LLC, Williams Jones Wealth Management LLC., New York State Common Retirement Fund, JPMorgan Chase & Co., Northern Trust Corp, and Group One Trading L.P..
View insider buying and selling activity for Spero Therapeutics or view top insider-selling stocks.

Which major investors are buying Spero Therapeutics stock?

SPRO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Eversept Partners LP, Rock Springs Capital Management LP, Walleye Capital LLC, Walleye Capital LLC, Dimensional Fund Advisors LP, GSA Capital Partners LLP, and Assenagon Asset Management S.A..
View insider buying and selling activity for Spero Therapeutics or or view top insider-buying stocks.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $1.24.

How much money does Spero Therapeutics make?

Spero Therapeutics has a market capitalization of $40.70 million and generates $18.26 million in revenue each year. The company earns $-89.76 million in net income (profit) each year or ($3.24) on an earnings per share basis.

How many employees does Spero Therapeutics have?

Spero Therapeutics employs 146 workers across the globe.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is sperotherapeutics.com.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at (857) 242-1600 or via email at [email protected].